Results 1 to 10 of about 53,085 (229)

Bortezomib-induced gastrointestinal dysfunction, peripheral neuropathy and neuroimmune signalling are influenced by the gut microbiota in mice [PDF]

Journal of Neuroinflammation
Background Peripheral neuropathy and gastrointestinal dysfunction are frequent, debilitating side effects of the neurotoxic myeloma drug bortezomib that reduce quality of life and adherence to optimal therapy.
Jacqui S. Scott, Sadia Munir, Miriam A. Lynn, Jvaughn A. Duggan, Joel Castro, Andrea M. Harrington, Stuart M. Brierley, Gudrun Schober, Kathy Cash, Bernice Gutschmidt, Mark R. Hutchinson, Angelina Yong, Samuel P. Costello, Suranjana Sikdar, Pawanrat Tangseefa, Duncan R. Hewett, Courtney B. Cross, Susanna B. Park, Feargal J. Ryan, Andrew C. W. Zannettino, David J. Lynn, Kate Vandyke, Hannah R. Wardill, Krzysztof M. Mrozik   +23 more
doaj   +2 more sources

Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. [PDF]

PLoS ONE, 2013
Previously, we reported that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates the apoptotic effect of bortezomib in hepatocellular carcinoma (HCC).
Hui-Chuan Yu, Duen-Ren Hou, Chun-Yu Liu, Chen-Si Lin, Chung-Wai Shiau, Ann-Lii Cheng, Kuen-Feng Chen   +6 more
doaj   +1 more source

In situ Electrochemical Evaluation of the Interaction of dsDNA with the Proteasome Inhibitor Anticancer Drug Bortezomib

Molecules, 2023
Bortezomib is an inhibitor of proteasomes and an anti-cancer drug. Although bortezomib is considered a safe drug, as confirmed by cytotoxicity assays, recent reports highlighted the possibility of interaction between bortezomib and cellular components ...
Mihaela-Cristina Bunea, Teodor Adrian Enache, Victor Constantin Diculescu   +2 more
doaj   +1 more source

Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition

Neoplasia: An International Journal for Oncology Research, 2022
The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival.
Melissa K. Bennett, Manjun Li, Melinda N. Tea, Melissa R. Pitman, John Toubia, Paul P.-S. Wang, Dovile Anderson, Darren J. Creek, Robert Z. Orlowski, Briony L. Gliddon, Jason A. Powell, Craig T. Wallington-Beddoe, Stuart M. Pitson   +12 more
doaj   +1 more source

Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. [PDF]

PLoS ONE, 2013
Bortezomib is an antitumor drug that competitively inhibits proteasome beta-1 and beta-5 subunits. While the impact of bortezomib on protein stability is known, the effect of this drug on intracellular peptides has not been previously explored.
Julia S Gelman, Juan Sironi, Iryna Berezniuk, Sayani Dasgupta, Leandro M Castro, Fabio C Gozzo, Emer S Ferro, Lloyd D Fricker   +7 more
doaj   +1 more source

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

Haematologica, 2015
Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking.
Meletios A. Dimopoulos, Robert Z. Orlowski, Thierry Facon, Pieter Sonneveld, Kenneth C. Anderson, Meral Beksac, Lotfi Benboubker, Huw Roddie, Anna Potamianou, Catherine Couturier, Huaibao Feng, Ozlem Ataman, Helgi van de Velde, Paul G. Richardson   +13 more
doaj   +1 more source

Characterization of bortezomib-adapted I-45 mesothelioma cells

Molecular Cancer, 2010
Background Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy.
Peddaboina Chander, Cao Xiaobo, Cui Yu, Littlejohn James E, Zhang Lidong, Smythe W Roy   +5 more
doaj   +1 more source

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma

Journal of Hematology & Oncology, 2018
Background Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib.
Zhihong Zheng, Shengjun Fan, Jing Zheng, Wei Huang, Cristina Gasparetto, Nelson J. Chao, Jianda Hu, Yubin Kang   +7 more
doaj   +1 more source

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure

EBioMedicine, 2015
The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib – exhibiting a low-nanomolar IC50 – suggesting
David S. Pitcher, Kate de Mattos-Shipley, Konstantinos Tzortzis, Holger W. Auner, Anastasios Karadimitris, Maurits F. Kleijnen   +5 more
doaj   +1 more source

Gabapentin Inhibits Bortezomib-Induced Mechanical Allodynia Through Supraspinal Action in Mice

Journal of Pharmacological Sciences, 2014
Bortezomib, an inhibitor of proteasome holoenzyme, is used to treat relapsed and refractory multiple myeloma. Peripheral neuropathy is a treatment-limiting adverse effect of bortezomib and is very difficult to control.
Ryo Kitamura, Tsugunobu Andoh, Shizuka Mizoguchi, Yukako Saito, Hiroki Takahata, Yasushi Kuraishi   +5 more
doaj   +1 more source